Scholar Rock Holdings Corporation (SRRK) Actualités

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular...

Form 4 - Statement of changes in beneficial ownership of securities

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Scholar Rock Reports Third Quarter 2024 Financial Results and Highlights Business Progress

- Reported positive topline data from pivotal Phase 3 SAPPHIRE trial evaluating apitegromab in patients with Spinal Muscular Atrophy (SMA...

Scholar Rock Announces New Preclinical Data for SRK-439 Showing Significant Lean Mass Increase and Enhanced Fat Mass Loss with Metformin

- Preclinical data show that SRK-439 increased lean mass and lowered fat mass gain in mice receiving metformin - Data support that Scholar...

Scholar Rock to Host Conference Call to Discuss Third Quarter 2024 Financial Results and Provide Business Update on November 12, 2024

Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA...

Scholar Rock to Participate in Upcoming Investor Conferences

Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA...

Scholar Rock to Present New Clinical and Biomarker Data from the Phase 1 DRAGON Trial at the SITC 39th Annual Meeting

Poster presentation to include new safety, efficacy, and biomarker data from the long-term expansion phase of the DRAGON trial in patients with...

Scholar Rock Announces Closing of Full Exercise of Option to Purchase Additional Shares in Public Offering

Scholar Rock Holding Corporation (Nasdaq: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal...

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular...

Form 8-K - Current report

Form 424B5 - Prospectus [Rule 424(b)(5)]

Scholar Rock Announces Pricing of Upsized $300 Million Public Offering of Common Stock and Pre-Funded Warrants

Scholar Rock Holding Corporation (Nasdaq: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities